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LETTER TO THE EDITOR
The M581V Mutation, Associated with a Mild Form of
Congenital Insensitivity to Pain with Anhidrosis, Causes
Partial Inactivation of the NTRK1 Receptor
To the Editor:
Congenital insensitivity to pain with anhidrosis (CIPA; MIM
256800), also known as hereditary sensory and autonomic
neuropathy type IV, is a rare autosomal recessive disorder associated
with consanguinity (Axelrod et al, 1984; Axelrod, 1996) and is
characterized by the absence of pain and temperature sensation and
the lack of sweating. CIPA patients are generally children; they
have recurrent episodes of unexplained fever, self-mutilation
behavior, and occasionally mental retardation (Rosemberg et al,
1994). CIPA is the consequence of a genetic defect in the
differentiation and migration of neural crest elements involved in
nociceptive reception as well as in thermal regulation. Recently,
mutations of the NTRK1 gene have been implicated in the
pathogenesis of this disease. So far 37 mutations of NTRK1 have
been detected in patients from different ethnic groups by several
laboratories, including ours. Mutation types include frameshift,
non-sense, splice site, and mis-sense (Indo, 2001).
The NTRK1 gene encodes one of the receptors of the nerve
growth factor (NGF). NTRK1 protein is a tyrosine kinase receptor
comprising an extracellular portion, involved in NGF binding, a
single transmembrane region, a juxtamembrane domain, a tyrosine
kinase domain, and a C-terminal tail. Most of CIPA mutations
occur within the NTRK1 tyrosine kinase domain and a few within
the extracellular domain. Recently, we analyzed the biologic effect
of several NTRK1 germline mis-sense mutations and discovered at
least three different pathogenic mechanisms responsible for the
disease. Most of the mutations inactivate the NTRK1 receptor by
completely abrogating its catalytic activity. The L213P mutation, in
the extracellular domain, interferes with the receptor processing,
causing its retention in the endoplasmic reticulum. The third
mechanism, described for mutation D668Y, involves a reduction of
the NTRK1 receptor activity, which is unlikely to be suf®cient for
the proper neuronal differentiation (Greco et al, 1999, 2000;
Miranda et al, 2002).
Recently the M581V mutation, occurring within subdomain V
(b5 strand) of the NTRK1 tyrosine kinase domain, has been
detected in a large Japanese CIPA family. The three affected
individuals were adults and displayed milder clinical symptoms
compared with other CIPA patients, including normal temperature
sensation and a relatively long survival. Two patients were
homozygous for the M581V mutation, whereas the third one
was a compound heterozygous with a combination of M581V
mutation and C1726 deletion (Yotsumoto et al, 1999).
We investigated the effect of the M581V mutation on NTRK1
receptor activity. The mutation was introduced into the NTRK1
cDNA subcloned into the pRC/CMV mammalian expression
vector, which carries the G418-resistance gene as a selectable
marker. The NTRK1/M581V and NTRK1/wt constructs were
transiently transfected into COS1 cells. Transfected cells were
treated with or without NGF (50 ng per ml) for 10 min or 16 h,
and cell extracts were immunoprecipitated with the MGR12
antibodies, which are speci®c for the receptor extracellular portion.
Western blot analysis with anti-TRK antibodies (reacting with the
intracellular NTRK1 portion) showed that the NTRK1/M581V
receptor produced the 110 and 140 kDa forms indicating its proper
expression (Fig 1A, upper panel). After western blot analysis with
anti-phosphotyrosine antibodies, we detected a basal autopho-
sphorylation of the wild-type receptor (due to the high expression
level), which increased after NGF treatment. With respect to the
NTRK1/M581V mutant, no phosphorylation was observed in
untreated cells. NGF treatment induced a weak phosphorylation,
highly reduced with respect to wild type, at 10 min and 16 h
(Fig 1A, lower panel). The low tyrosine phosphorylation level
achieved by NTRK1/M581V mutant after a long NGF treatment
suggests a defect in the intrinsic kinase activity, rather than in the
autophosphorylation kinetics. To investigate whether a deregulated
phosphatase activity might account for the reduced phosphoryl-
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Figure 1. Biochemical analysis of NTRK1 receptor carrying the
M581V mutation. The M581V mutation was introduced by site-
directed mutagenesis (Gene Editor, Promega) into the NTRK1 cDNA
inserted into the pRC/CMV expression vector. The sequence of the
oligonucleotide is the following: 5¢CCCTGCTCGTGGTCTTCG3¢ (the
mutated nucleotide is underlined). Mutated clones were identi®ed by
nucleotide sequence of a PCR fragment spanning the mutation. A
selected mutant clone was subjected to a complete nucleotide sequence
to exclude possible additional mutations that accidentally occurred during
the mutagenesis reaction. One microgram of the indicated plasmid DNA
was transfected in combination with 19 mg of carrier pRC/CMV DNA
into COS1 cells as previously described (Miranda et al, 2002). Two days
later, cells were serum starved overnight then subjected to the indicated
treatments. (A) Expression (top) and phosphorylation (bottom) of wild-
type and mutated proteins. Cells were treated with 50 ng NGF per ml
for the indicated times, lyzed with PLCLB buffer and subjected to
immunoprecipitation using MGR12 antibodies directed towards the
extracellular portion of NTRK1 (Tagliabue et al, 1999).
Immunoprecipitates were resolved in 6.5% sodium dodecyl sulfate±
polyacrylamide gel electrophoresis then subjected to western blotting
with anti-TRK (Santa Cruz Biotechnology, Inc.) or anti-
phosphotyrosine (Upstate Biotecnology, Inc.) antibodies and revealed by
enhanced chemiluminescence (Amersham Biosciences). (B) Effect of
sodium orthovanadate (Na3VO4) on NTRK1/M581V tyrosine
phosphorylation. Transfected COS1 cells were treated with 5 mM
Na3VO4 for 2.5 h then subjected to western blot analysis as described
above.
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ation of the NTRK1/M581V receptor, we treated transfected cells
with sodium orthovanadate, a phosphatase inhibitor. The level of
NTRK1/M581V receptor tyrosine phosphorylation increased in
the presence of the inhibitor, and was detectable also in the absence
of NGF stimulation (compare Fig 1B and A); however, the
phosphorylation of the NTRK1/M581V receptor was signi®cantly
lower than wild type, both in the absence and in the presence of
NGF, despite the similar protein expression levels. These data
suggest that the M581V mutation interferes with the autopho-
sphorylation of the NTRK1 receptor rather than with its
downregulation by phosphatases. Most likely the M581V mutation
introduces structural changes in the NTRK1 tyrosine kinase
domain so that the receptor responsiveness is reduced.
To determine the biologic effect of the M581V mutation we
performed NIH3T3 transfection/focus forming assay, based on the
ability of NGF-stimulated NTRK1 receptor to induce NIH3T3
transformation. This analysis has been successfully used to study the
biologic activities of several NTRK1/CIPA mutants, and in
particular to demonstrate the reduction of activity induced by the
D668Y mutation (Greco et al, 1999, 2000; Miranda et al, 2002).
Ten nanograms of NTRK1/wt, NTRK1/M581V, and NTRK1/
D668Y plasmid DNA/2 3 105 cells were transfected; foci were
selected in the absence or in the presence of 1 and 2 ng per ml of
NGF. As shown in Fig 2, wild-type NTRK1 produced foci in the
presence of both 1 and 2 ng per ml of NGF, in agreement with
previous data (Miranda et al, 2002). The M581V receptor produced
foci only in the presence of 2 ng per ml of NGF, with strongly
reduced ef®ciency with respect to the wild type. The transforming
activity of D668Y mutant, used as a control, was signi®cantly
reduced with respect to the wild type, as previously reported
(Miranda et al, 2002), but slightly higher than M581V.
We have shown that the M581V mutation causes a reduction of
activity of the NTRK1 receptor and therefore we have identi®ed
an important residue for receptor activity. The molecular structure
of NTRK1 receptor remains unsolved; however, a model of its
inactive and active forms can be produced by analogy of the insulin
receptor kinase. In this model methionine 581 is totally buried in a
hydrophobic environment. Valine, despite being equally hydro-
phobic, is de®nitely smaller and could cause destabilization of this
part of the molecule leading to a reduction in receptor respon-
siveness but not to complete inactivation. Thus, the residual activity
may be suf®cient for some of the NGF effects, and would explain
the mild phenotype of the CIPA patients carrying the M581V
mutation.
In conclusion, our data indicate that a reduction in NTRK1
receptor activity may be a common mechanism in CIPA disease,
being ascribed to two different mutations, the D668Y and the
M581V, so far reported.
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Figure 2. Transforming activity of NTRK1/M581V protein.
NIH3T3 cells (2.5 3 105 per 100 mm dish) were transfected with 10 ng
of the indicated plasmid DNA by the calcium phosphate precipitation
method, using 30 mg of HMW NIH3T3 DNA as carrier. Transfected
cells were selected either in G418-containing medium, to determine
transfection ef®ciency, or in 5% serum medium, supplemented or not
with NGF, to determine transforming activity. G418-resistant colonies
and transformed foci were ®xed and stained after 2 wk of selection. (A)
Transforming activity was calculated by normalizing the number of
transformed foci for that of G418-resistant colonies. (B) Transformed foci
selected in 1 and 2 ng per ml of NGF are shown.
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